| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02817113 Details | 2021-04-30 Interventional | 1 | 4 | Cetuximab Fluorouracil Head and Neck N… | Strategy change - | |||
| NCT02038699 Details | 2021-04-30 Interventional | 1/2 | 0 | TIC10 compound Glioblastoma Triple Negative… Advanced Colore… Advanced Gliobl… Advanced Non-sm… Advanced Triple… | Protocol not activated. - | |||
| NCT00784693 Details | 2021-04-30 Interventional | 2 | 48 | Tanezumab Endometriosis | Further recruitment into the study was ceased on 10th December 2009, not attributed to safety.
All patients recruited in the study completed all study visits. Nerve growth factor (NGF) results were reported only for plasma since a reliable assay was not available for analyzing NGF in urine. Study was prematurely terminated and recruitment was stopped due to futility shown in pre-planned interim analysis. | |||
| NCT04374942 Details | 2021-04-29 Interventional | 3 | 13 | Hydroxychloroqu… Coronavirus Inf… Coronavirus Pre-Exposure Pr… SARS-CoV 2 | Due to unproven issues associated with hydroxychloroquine use and safety, further complicated
by media and political misinformation which in effect rendered all global studies on HCQ to
stop enrolling participants. - | |||
| NCT03935815 Details | 2021-04-28 Interventional | 1 | [5 Refs] | 26 | Ropivacaine Laparoscopic My… Quadratus Lumbo… | Closed prior to completion secondary to surgeon leaving UCLA - | ||
| NCT03846258 Details | 2021-04-28 Interventional | 4 | 0 | Pharmaceutical … Acidosis Acute Kidney In… Renal Insuffici… Acute Kidney Fa… Metabolic Acido… | Due to the fact that we were unable to find subjects who met all inclusion and exclusion
criteria it was determined to withdraw this study. - | |||
| NCT03348735 Details | 2021-04-28 Interventional | 4 | 33 | Capsaicin Lidocaine Pregabalin Neuralgia Neuropathic Pai… | Low inclusion rate - | |||
| NCT02651116 Details | 2021-04-28 Interventional | 4 | 131 | Dextromethorpha… Levomethorphan Cough | The study was prematurely discontinued due to slow enrollment during the 2019/2020 cold season.
No safety or efficacy concerns led to the decision to terminate - | |||
| NCT01185366 Details | 2021-04-28 Interventional | 2 | 73 | Everolimus Sunitinib Carcinoma Carcinoma, Rena… Kidney Neoplasm… Kidney Cancer | - - | |||
| NCT04365582 Details | 2021-04-27 Interventional | 3 | 0 | Azithromycin Hydroxychloroqu… Lopinavir Ritonavir COVID | The PI decided. - | |||
| NCT04126044 Details | 2021-04-27 Interventional | 1 | 0 | Bevacizumab Pharmacokinetic… | The study was withdrawn prior to enrollment after a comprehensive review of the biosimilars
market and the company's global manufacturing network. - | |||
| NCT03426137 Details | 2021-04-27 Interventional | 2 | 3 | Ketorolac Oxycodone Acute Pain Opioid Use Spine Fusion Trauma | The focus of the project has shifted to publishing a protocol for future trials because we were
unable to recruit. Three participants signed the consent forms but withdrew before the
randomization. Early termination due to logistical and funding issues, which lead to no analyzable data. A protocol paper has been published should other investigators wish to use the study design (DOI: 10.1136/bmjopen-2019-030623). | |||
| NCT03051672 Details | 2021-04-27 Interventional | 2 | [1 Refs] | 8 | Pembrolizumab Breast Neoplasm… Metastatic Brea… | Based on two-stage design, the study ended at stage 1 with no evidence of promise based on
pre-specified decision rule. - | ||
| NCT01999335 Details | 2021-04-27 Interventional | 1 | 33 | Dexamethasone Pomalidomide Multiple Myelom… Neoplasms, Plas… | A program evaluation identified that the safety profile and pharmacokinetic (PK)
characteristics of the formulation used in all oprozomib studies required further optimization
and thus enrollment in OPZ007 was halted during dose-expansion. - | |||
| NCT04455958 Details | 2021-04-26 Interventional | 2 | 0 | Lopinavir Ritonavir COVID-19 Laboratory Infe… Neoplasms Hematopoietic a… Malignant Solid… Symptomatic COV… | limited resources - | |||
| NCT04303377 2018-001065-17 Details | 2021-04-26 Interventional | 2 | 0 | Evolocumab Infarction Myocardial Infa… ST Elevation My… ST-elevation My… | The sponsor required early termination of the economic agreement due to a supposed extension of
the enrollment period for bureaucracy reasons and for the concomitant Covid -19 Pandemic - | |||
| NCT01972854 Details | 2021-04-26 Interventional | 3 | 92 | Pharmaceutical … Riboflavin Keratoconus | - - | |||
| NCT01893359 Details | 2021-04-26 Interventional | 1/2 | 2 | Dextrans Ophthalmic Solu… Riboflavin Astigmatism Hyperopia Hyperopic Astig… | - - | |||
| NCT01643252 Details | 2021-04-26 Interventional | 3 | 0 | Ophthalmic Solu… Pharmaceutical … Riboflavin Corneal Disease… Dilatation, Pat… Corneal Ectasia | This study was withdrawn for business reasons. - | |||
| NCT04663269 Details | 2021-04-23 Interventional | 4 | 5 | Dexamethasone Kidney Calculi Kidney Stone Surgery | Drop out from surgeons from 3 to 1. It will take too long to feasibly accrue with only one
provider. - |